What is Precisis?
Founded in 2004, Precisis AG specializes in the development of innovative medical devices, particularly in the realm of instrument-controlled therapies for the brain. The company is recognized for its advancements in neurostimulation, focusing on creating individually tailored and precise treatment methods to enhance the lives of patients with serious neurological conditions. Precisis AG operates with a strong commitment to ethical considerations and responsible technological application, developing reliable solutions for individuals suffering from functional brain disorders in collaboration with key partners. Their work is centered around improving patient outcomes through cutting-edge technology.
How much funding has Precisis raised?
Precisis has raised a total of $23.2M across 1 funding round:
Other Financing Round
$23.2M
Other Financing Round (2021): $23.2M with participation from Cochlear
Key Investors in Precisis
Cochlear
Cochlear is a global leader in implantable hearing solutions, known for its advanced medical devices. Their investment in Precisis AG suggests a strategic interest in complementary medical technologies, potentially for neurostimulation applications.
What's next for Precisis?
The substantial enterprise-level funding and recent strategic investment indicate that Precisis AG is poised for significant scaling and further innovation. This capital infusion will likely accelerate the development and commercialization of their neurostimulation technologies, potentially expanding their market reach and impact. The company's focus on precision therapies for brain disorders positions them to address critical unmet needs in the medical field. Future endeavors may include further clinical trials, broader market penetration, and the development of next-generation devices to enhance patient care and quality of life.
See full Precisis company page
